RE:Trucchio @Wainwright...If you calculate the market value based on the science there has always been an argument that the share price has been always under valued. The big money has always understood that ONCY never has enough money to ever do much of anything other than keep the lights on. Every dilution is just enough to cover g&a with the hope that successful trial results will once again propel it higher. Now these type of results barely move the needle. Of course the fireside chats are a complete waste of time. Relevant questions like, "why can't you entice a BP", are never asked. Currently, it would appear there is one logical BP, Roche. If this is the case there is no need for them to rush into a deal with ONCY because the chances are slim someone else will leap frog them and make an offer. This could also mean any forthcoming offer will not reflect the true value. If (big if) another BP was interested then the picture could change. As has been discussed before an AA would change this scenario because then there would be a revenue stream and the onus would fall back to the likes of Roche to come to the table quickly. However, the longer this goes without an approval the less likely it will happen. One thing seems certain positive trial results at this stage aren't going to prople the sp. The market is telling us that, so as usual we wait with baited breath the BP announcement.